scispace - formally typeset
J

Julia Tischler

Researcher at Wellcome Trust/Cancer Research UK Gurdon Institute

Publications -  21
Citations -  3011

Julia Tischler is an academic researcher from Wellcome Trust/Cancer Research UK Gurdon Institute. The author has contributed to research in topics: Gene & Embryonic stem cell. The author has an hindex of 15, co-authored 18 publications receiving 2805 citations. Previous affiliations of Julia Tischler include University of Vienna & Medical University of Vienna.

Papers
More filters
Journal ArticleDOI

Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression

TL;DR: This study provides the first evidence that a histone deacetylase is essential for unrestricted cell proliferation by repressing the expression of selective cell cycle inhibitors.
Journal ArticleDOI

Systematic mapping of genetic interactions in Caenorhabditis elegans identifies common modifiers of diverse signaling pathways.

TL;DR: It is proposed that these genes function as general buffers of genetic variation and that these hub genes may act as modifier genes in multiple, mechanistically unrelated genetic diseases in humans.
Journal ArticleDOI

Dynamic heterogeneity and DNA methylation in embryonic stem cells.

TL;DR: It is found that DNA methylation plays a key role in maintaining these metastable states and the “2i” signaling pathway inhibitors modulate both types of variation.
Journal ArticleDOI

Negative and positive regulation of gene expression by mouse histone deacetylase 1.

TL;DR: This study reveals a regulatory cross talk between HDAC1 and HDAC2 and a novel function forHDAC1 as a transcriptional coactivator and a new set of genes found to require HDAC activity and recruitment of HDac1 for their transcriptional activation.
Journal ArticleDOI

The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene.

TL;DR: The findings show that the deacetylase HDAC1 acts as an antagonist of the tumor suppressor p53 in the regulation of the cyclin-dependent kinase inhibitor p21 and provide a basis for understanding the function of histone deacetyase inhibitors as antitumor drugs.